|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AlphaVax Inc., of Research Triangle Park, N.C., began immunizing volunteers in trials to evaluate vaccines for cytomegalovirus (CMV) and influenza developed with the company's alphavaccine technology. In the first, they're receiving a human version of an alphavaccine that's shown to be effective in protecting against congenital CMV disease in a preclinical study. Results will be used to design future studies in target populations such as solid organ transplant recipients. In the second, volunteers are being immunized with a flu alphavaccine that contains the hemagglutinin gene from a single flu strain and has been shown to be effective in protecting animals against ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cougar Biotechnology Announces Agreement with FDA on Special ...
Business Wire;
February 10, 2009 ;
700+ words
... ... regarding the Company's Phase III trial design and ability ... Pursuant to the SPA, the Phase III trial will be a randomized ... North America, Europe and Australia. The agreed upon co ... patient enrollment in this Phase III trial later this quarter ...
|
|